CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Close

Trade Novavax NVAX

Sell
 Buy

Novavax live chart

5m 15m 30m 1h 4h 1d 1w

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2025 Dec 05, 22:05

Novavax, Inc. (NVAX): A Bull Case Theory

Novavax Inc
Webhose 2025 Dec 04, 07:12

Novavax (NVAX): Exploring Valuation After Prolonged Share Price Weakness

Novavax Inc
Webhose 2025 Dec 04, 01:27

Is Novavax Now a Bargain After a 94.1% Five Year Share Price Slump?

Novavax Inc
Webhose 2025 Dec 01, 17:09

Vaccine makers fall on FDA memo, Bally's wins bid for NYC casino

Novavax Inc
Webhose 2025 Nov 28, 00:28

Novavax (NVAX) Valuation: Assessing the Shift to Partnerships and an R&D-Focused Strategy - Simply Wall St News

Novavax Inc
Webhose 2025 Nov 26, 18:25

Novavax call volume above normal and directionally bullish | Markets Insider

Novavax Inc
Webhose 2025 Nov 26, 03:11

What Recent Partnership Efforts Mean for the Value of Novavax in 2025

Novavax Inc
Webhose 2025 Nov 25, 13:39

Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast

Novavax Inc
Webhose 2025 Nov 21, 06:34

JPMorgan Chase & Co. Cuts Novavax (NASDAQ:NVAX) Price Target to $6.00 - Stock Observer

Novavax Inc
Webhose 2025 Nov 19, 16:16

JPMorgan Chase & Co. Issues Pessimistic Forecast for Novavax (NASDAQ:NVAX) Stock Price

Novavax Inc
Webhose 2025 Nov 19, 03:21

Novavax (NVAX): Evaluating Valuation Gaps as Shares Extend Recent Slide

Novavax Inc
Webhose 2025 Nov 18, 08:16

JPMorgan Chase & Co. Lowers Novavax (NASDAQ:NVAX) Price Target to $6.00 - Daily Political

Novavax Inc
Webhose 2025 Nov 17, 07:34

Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $11.38 - Markets Daily

Novavax Inc
Webhose 2025 Nov 17, 05:52

Investment Analysts' Weekly Ratings Changes for Novavax (NVAX) - Stock Observer

Novavax Inc
Webhose 2025 Nov 15, 11:16

Jupiter Asset Management Ltd. Buys 582,858 Shares of Novavax, Inc. $NVAX

Novavax Inc
Webhose 2025 Nov 15, 06:54

Novavax, Inc. (NASDAQ:NVAX) Receives Consensus Recommendation of "Hold" from Brokerages

Novavax Inc

Novavax news

Latest news

Show more

Info

Spread

0.05

Spread (%)

0.7508 %

Leverage

1:5

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Friday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Wednesday

14:31-20:59

Thursday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1067618432

Shares Outstanding

162498995

Earnings Date (Next)

2019-05-10

Div Yield

2019-05-10

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

1.97

Learn more about this instrument

Novavax Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Related Instruments

Asset
Sell
Buy
Change (%)

Trade Now

Trade Now

Trade Now

Trade Now
View all instruments

latest_education_articles

Show more
Trustpilot